Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.

Nat Commun · 2024 · PMC10928200 · PMID 38467604

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

did not reach statistical significanceP = 0.16not close (p > 0.1)

4e , the TP53 alternation was more common in HPV - patients ( P < 0.001), while the TERT alternation was also more common in HPV - patients, although the difference did not reach statistical significance ( P = 0.16).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.